H. Gruell

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope
20262 citationsauthor #33
Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults
20260 citationsauthor #3
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.
20260 citationsauthor #32
Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals.
20260 citationsauthor #22
Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5
20250 citationsauthor #32
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy
20250 citationsauthor #4
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation
20254 citationsauthor #32
Diverse clinical manifestations of Parvovirus B19 infections during the 2024 outbreak in Germany
20253 citationsauthor #4
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
20252 citationsauthor #4
Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024
20250 citationsauthor #9
Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients
20251 citationsauthor #12
In-hospital environmental surface and air contamination by monkeypox virus clade Ib in Germany.
20250 citationsauthor #5
Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
20254 citationsauthor #22
Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope
20251 citationsauthor #33
Fatal dengue virus infection in an unvaccinated traveler
20240 citationsauthor #16
Therapeutic interfering particles against HIV: molecular parasites reducing viremia
20241 citationsauthor #1
Respiratory syncytial virus infection in patients with haematological diseases: a retrospective multicentre study
20247 citationsauthor #10
Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration
20241 citationsauthor #7
Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymphocytic leukemia
20242 citationsauthor #7
Does CAR T-Cell Level during Post-CART DLBCL Progression Influence the Response to Salvage Radiotherapy and Patient Outcomes?
20240 citationsauthor #6
Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape
20231 citationsauthor #9
Dynamics and durability of HIV-1 neutralization are determined by viral replication
202310 citationsauthor #12
Advancing bnAb combinations for HIV prevention.
20234 citationsauthor #1
Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool
202328 citationsauthor #9
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa.
202331 citationsauthor #13
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer.
202313 citationsauthor #10
Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants.
202324 citationsauthor #9
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients
20238 citationsauthor #14
15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study
20239 citationsauthor #9
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
202318 citationsauthor #3
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
20239 citationsauthor #33
Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome
20239 citationsauthor #17
Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals
202310 citationsauthor #9
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
202254 citationsauthor #1
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
202211 citationsauthor #2
Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient Patients
20222 citationsauthor #4
Antibody-mediated neutralization of SARS-CoV-2
2022113 citationsauthor #1
Title: A naturally arising broad and potent CD4-binding site antibody with low somatic mutation 1 Short Title: An HIV-1 bNAb with low somatic mutation
20220 citationsauthor #6
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia
20227 citationsauthor #6
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
202266 citationsauthor #1
National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review
202215 citationsauthor #15
Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals
202215 citationsauthor #7
Broadly neutralizing antibodies against HIV-1 and concepts for application.
202231 citationsauthor #1
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
202217 citationsauthor #6
Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France
20223 citationsauthor #2
Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals
20225 citationsauthor #9
Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals
20222 citationsauthor #3
Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
202242 citationsauthor #4
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
202237 citationsauthor #1
Delineating antibody escape from Omicron sublineages
202210 citationsauthor #1
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
202232 citationsauthor #3
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
20219 citationsauthor #15
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
202114 citationsauthor #7
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
2021139 citationsauthor #8
Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19
20215 citationsauthor #9
Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patients
20219 citationsauthor #6
Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals
202157 citationsauthor #12
Running title: Estimating SARS-CoV-2 infectiousness by a RADT
20211 citationsauthor #10
Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
202111 citationsauthor #5
Stochasticity of infectious outbreaks and consequences for optimal interventions
20211 citationsauthor #2
Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study
2021613 citationsauthor #6
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia
202127 citationsauthor #6
The Alpha Variant (B.1.1.7) of SARS-CoV-2 in Children: First Experience from 3544 Nucleic Acid Amplification Tests in a Cohort of Children in Germany
202126 citationsauthor #4
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
202125 citationsauthor #10
Contact-dependent inhibition of HIV-1 replication in ex vivo human tonsil cultures by polymorphonuclear neutrophils
20215 citationsauthor #5
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
202149 citationsauthor #10
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
202155 citationsauthor #5
COVID‐19 study found that 0.4% of 5730 asymptomatic children aged 0–18 years tested positive for virus before hospital procedures or admission
20216 citationsauthor #3
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
2021391 citationsauthor #1
Reliable assessment of in vitro SARS-CoV-2 infectivity by a Rapid Antigen Detection Test
20213 citationsauthor #12
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
202127 citationsauthor #4
CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention
20213 citationsauthor #4
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
202150 citationsauthor #5
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
2021314 citationsauthor #16
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
202150 citationsauthor #8
Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19
2021119 citationsauthor #20
Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
202022 citationsauthor #3
Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies
202020 citationsauthor #2
Intensified adjunctive corticosteroid therapy for CNS tuberculomas
202013 citationsauthor #2
Rapid Response Infrastructures for Pandemic Preparedness in Tertiary Care Hospitals: Lessons Learned from the COVID-19 Outbreak in Germany
20200 citationsauthor #5
SARS-CoV-2 targets cortical neurons of 3D human brain organoids and shows neurodegeneration-like effects
202026 citationsauthor #9
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
202014 citationsauthor #10
A novel humanized mouse model to study mucosal HIV-1 transmission and prevention
20202 citationsauthor #4
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
2020127 citationsauthor #2
The SARS-CoV-2 spike protein primes inflammasome-mediated interleukin-1- beta secretion in COVID-19 patient-derived macrophages
202017 citationsauthor #13
Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?
202012 citationsauthor #4
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
2020135 citationsauthor #10
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
2020326 citationsauthor #9
SARS‐CoV‐2 targets neurons of 3D human brain organoids
2020406 citationsauthor #9
Safe and effective pool testing for SARS-CoV-2 detection
202011 citationsauthor #12
COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia
20208 citationsauthor #3
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
20202 citationsauthor #26
Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020
202016 citationsauthor #5
Systematic Review And Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.
20199 citationsauthor #5
Novel highly potent CD4bs bNAb with restricted pathway to HIV-1 escape
20190 citationsauthor #2
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
2019101 citationsauthor #7
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
201988 citationsauthor #7
Antibody-mediated prevention and treatment of HIV-1 infection
201856 citationsauthor #1
Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption
201869 citationsauthor #5
Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
2018229 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT